CASI Pharmaceuticals Newsroom

CASI Pharmaceuticals Faces Clinical Hold on CID-103 by FDA

TipRanksDec 26 21:57

Express News | CASI Pharmaceuticals: Accrual to Phase 1-2 Study of Cid-103 Expected to Commence in Q1 2025

BreakingsDec 26 21:32

Express News | CASI Pharmaceuticals: Cid-103 Ind Application Supporting Phase 1-2 Study of Cid-103 in Adults With Chronic Immune Thrombocytopenia Remains Open

BreakingsDec 26 21:32

Express News | CASI Pharmaceuticals: FDA Plans to Provide Formal Written Response Before Statutory Deadline

BreakingsDec 26 21:31

Express News | CASI Pharmaceuticals Inc: Announces Clinical Hold of Cid-103 for Antibody Mediated Rejection (Amr) of Kidney Transplant

BreakingsDec 26 21:30

Express News | CASI Pharmaceuticals Inc Files for Mixed Shelf Offering of up to $200 Mln- SEC Filing

BreakingsDec 21 06:28

CASI Pharmaceuticals Faces Evomela License Termination Dispute

TipRanksDec 16 21:27

Express News | CASI Pharmaceuticals: On Dec 13, Got Termination Process Letter for License of Evomela From Acrotech Biopharma

BreakingsDec 16 21:12

Aviation Safety Solutions and Corporate Aviation Security International Join Forces to Fill Needed Gap in Aviation Safety and Security

PR NewswireDec 12 21:00

Express News | CASI Pharmaceuticals - Qtrly Shr Loss $0.55

BreakingsNov 15 21:33

Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q3 Revenue $7.8M

MT NewswiresNov 15 21:25

Earnings Scheduled For November 14, 2024

BenzingaNov 14 16:32

Here's the Major Earnings Before the Open Tomorrow

Seeking AlphaNov 14 07:00

CASI Pharmaceuticals Q3 Earnings Preview

Seeking AlphaNov 14 01:20

Earnings Preview: CASI to Report Financial Results Pre-market on November 14

$CASI Pharmaceuticals(CASI.US)$ is scheduled to release its financial results pre-market on November 14 ET. Earnings PreviewAnalysts estimate $CASI Pharmaceuticals(CASI.US)$ to post revenue of USD4.56

Futu NewsNov 9 09:00

Casi Pharmaceuticals Says China Cleared Phase 1/2 Trial in Immune Thrombocytopenia

MT NewswiresOct 24 23:16

CASI Pharmaceuticals Receives Clinical Trial Application Approval From China's NMPA To Proceed With Phase 1/2 Study Of CID-103 In Immune Thrombocytopenia

BenzingaOct 24 20:07

12 Health Care Stocks Moving In Tuesday's After-Market Session

BenzingaOct 2 04:31

CASI Pharmaceuticals (NASDAQ:CASI) Shareholders Are Still up 129% Over 1 Year Despite Pulling Back 22% in the Past Week

Yahoo FinanceSep 27 01:18

Express News | CASI Pharmaceuticals Inc - Effective From Sept 10, Position of President of Co Was Removed

BreakingsSep 12 19:33